Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant neoplasm arising from adipocytes, that occurs in adults. The tumor maybe one of several histologic types including well-differentiated, dedifferentiated, myxoid/round cell, and pleomorphic liposarcoma.
Biomarker and diagnostic research for adult liposarcoma has been reported in the published literature.
55 clinical trials registered, 31 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 18 PHASE2, 26 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06843967](https://clinicaltrials.gov/study/NCT06843967) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:56 PM UTC
Common questions about adult liposarcoma
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma |
PHASE1 |
Memorial Sloan Kettering Cancer Center |
RECRUITING |
[NCT07432932](https://clinicaltrials.gov/study/NCT07432932) | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients | — | Royal Marsden NHS Foundation Trust | RECRUITING |
[NCT04785196](https://clinicaltrials.gov/study/NCT04785196) | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | PHASE1 | Ascentage Pharma Group Inc. | RECRUITING |
[NCT06389799](https://clinicaltrials.gov/study/NCT06389799) | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | PHASE2 | Lund University Hospital | RECRUITING |
[NCT06957431](https://clinicaltrials.gov/study/NCT06957431) | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | PHASE1 | Washington University School of Medicine | RECRUITING |
169 publications have been identified in PubMed for adult liposarcoma. Kisho has analyzed 58 by research type. Research spans Review / Meta-Analysis (29%), Basic Science / Preclinical (29%), and Case Report / Case Series (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 17 | 29% |
Laboratory research | 17 | 29% |
Patient case studies | 6 | 10% |
Clinical study results | 6 | 10% |
Testing and diagnosis research | 4 | 7% |
Disease patterns and progression | 4 | 7% |
Other research | 2 | 3% |
New treatment approaches | 2 | 3% |
Jin C (2026). [PMID: 41763312](https://pubmed.ncbi.nlm.nih.gov/41763312/). *J Biol Chem*. [Basic Science / Preclinical]
Pimenta EM (2026). [PMID: 41564157](https://pubmed.ncbi.nlm.nih.gov/41564157/). *Sci Transl Med*. [Clinical Trial Publication]
Nishio J (2026). [PMID: 41482346](https://pubmed.ncbi.nlm.nih.gov/41482346/). *Cancer Genomics Proteomics*. [Review / Meta-Analysis]
Zhang L (2026). [PMID: 41514406](https://pubmed.ncbi.nlm.nih.gov/41514406/). *Eur J Med Res*. [Basic Science / Preclinical]
Menon G (2026). [PMID: 30855853](https://pubmed.ncbi.nlm.nih.gov/30855853/). *Unknown Journal*. [Basic Science / Preclinical]
Rodenko PN (2025). [PMID: 40662008](https://pubmed.ncbi.nlm.nih.gov/40662008/). *Cureus*. [Case Report / Case Series]
Huergo C (2025). [PMID: 41079930](https://pubmed.ncbi.nlm.nih.gov/41079930/). *Int J Biol Sci*. [Epidemiology / Natural History]
Farooq MS (2025). [PMID: 40358214](https://pubmed.ncbi.nlm.nih.gov/40358214/). *J Surg Oncol*. [Epidemiology / Natural History]
Shafer AM (2025). [PMID: 40928975](https://pubmed.ncbi.nlm.nih.gov/40928975/). *Clin Cancer Res*. [Basic Science / Preclinical]
Dwianingsih EK (2025). [PMID: 40747377](https://pubmed.ncbi.nlm.nih.gov/40747377/). *Oncol Lett*. [Review / Meta-Analysis]